"東京品川区にある総合病院。ＪＲ京浜東北線大井町駅中央口（中央東方面 きゅりあん側）より徒歩７分。夜間休日救急も対応しております。 2018年4月に東芝病院より経営移譲し、それまでの内科系の強みに加え、脳神経外科、脊髄脊椎外科、呼吸器内科、人間ドック、乳腺外科、整形外科、形成外科、血管外科といった外科系の体制も整えました。産婦人科、腎臓内科、小児科、泌尿器科もございます。 ER（救急救命室）やHCU（ハイケアユニット）を新設し、24時間365日、土日や夜間でも、重症な患者さまや緊急手術に対応できるような環境を整備しておりますので発熱外来や救急外来もご相談ください。 また回復期リハビリテーション病棟も設置し、急性期治療後の充分なリハビリを行い在宅復帰を目指しています。 健診センターの機能も充実させ、予防医学として人間ドックでの5大がん健診（胃がん、大腸がん、肺がん、乳がん、肝がん）や胃カメラ、内視鏡、脳ドック等も注力し、早期発見・早期治療に努め、皆さまの健康と生活を守りたいと考えております。 2019年10月には産科も再開し、無痛分娩をはじめ総合病院ならではの充実した医療環境の中で安心して出産していただけるお手伝いをいたします。 お気軽にご来院ください。 #東京 #総合病院 #夜間休日救急 #脳神経外科 #血液透析 #がん検診 #脳ドック #突発性難聴 #大森 #循環器内科 #胃カメラ #品川区 #内視鏡 #人間ドック #産婦人科 #消化器内科 #乳がん #整形外科 #呼吸器内科 #腎臓内科 #むくみ #心筋梗塞 #人工関節 #白内障"

During the past decade, Tokyo Shinagawa Hospital Medical Corporation Association Tokyokyojuno-kai conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 1 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tokyo Shinagawa Hospital Medical Corporation Association Tokyokyojuno-kai" #1 collaborator was "Atea Pharmaceuticals, Inc." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Tokyo Shinagawa Hospital Medical Corporation Association Tokyokyojuno-kai" are "Influenza" (2 trials) and "COVID-19" (1 trials). Many other conditions were trialed in "Tokyo Shinagawa Hospital Medical Corporation Association Tokyokyojuno-kai" in a lesser frequency.

Most popular intervention types in "Tokyo Shinagawa Hospital Medical Corporation Association Tokyokyojuno-kai" are "Drug" (3 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Baloxavir Marboxil" (2 trials) and "RO7496998" (1 trials). Other intervention names were less common.

The vast majority of trials in "Tokyo Shinagawa Hospital Medical Corporation Association Tokyokyojuno-kai" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Tokyo Shinagawa Hospital Medical Corporation Association Tokyokyojuno-kai". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Tokyo Shinagawa Hospital Medical Corporation Association Tokyokyojuno-kai, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Tokyo Shinagawa Hospital Medical Corporation Association Tokyokyojuno-kai, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".